Recently, in an established xenograft mouse model of colon cancer, the drug ML264 efficiently inhibited growth of the tumor within 5 days of treatment by inhibiting the expression of KLF5 and EGR1, a transcriptional activator of KLF5 [39]. Here, KLF5 is linked to malignant colon neoplasm.